Two-Part, Open-Label, Multi-Center, Phase 1/2 Study of BIW-8962 as Monotherapy in Subjects With Lung Cancer

NCT01898156 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

37

Enrollment

INDUSTRY

Sponsor class

Stopped lack of efficacy

Conditions

Phase 1 Portion : Non Small Cell Lung Cancer(NSCLC), Small Cell Lung Cancer(SCLC), Mesothelioma
Phase 2 Portion : Small Cell Lung Cancer(SCLC)

Interventions

DRUG: BIW-8962

Sponsor

Kyowa Kirin Korea Co., Ltd.